ARS Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SPRY
Original HTML
ARS Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SPRY
LOS ANGELES, Sept. 8, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against ARS Pharmaceuticals, Inc. ("ARS" or "the Company") (NASDAQ: SPRY) violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Shareholders who purchased shares of SPRY during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.
CLASS PERIOD: March 9, 2026 to June 24, 2026
DEADLINE: October 5, 2026
CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. ARS knew its timeline for CVS Caremark formulary and coverage approval decisions for neffy faced issues. The Company's commercialization plans would be impacted by this delay. Based on these facts, ARS's public statements were false and materially misleading throughout the class period.
If you are a shareholder who suffered a loss, contact us to participate.
WHY DJS LAW GROUP? DJS Law Group's David Schwartz is a founding partner of Schall Brown & Schwartz LLP, and his primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.
Join the case to recover your losses.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
David J. Schwartz
DJS Law Group
274 White Plains Road, Suite 1
Eastchester, NY 10709
Phone: 914-206-9742
Email: [email protected]
SOURCE DJS Law Group LLP
Share this article
Original Summary
<p>LOS ANGELES, Sept. 8, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against ARS Pharmaceuticals, Inc. ("ARS" or "the Company") (NASDAQ: SPRY) violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder...</p>
Generated Article_json
{"target_audience": "b2b", "is_medical": false, "ai_generated_title": "ARS Pharmaceuticals Faces Securities Class Action Over Neffy Approval Delays", "body_html": "<p><strong>Los Angeles -- [CURRENT_DATE] --</strong> DJS Law Group has filed a securities class action against ARS Pharmaceuticals, Inc. (NASDAQ: SPRY), alleging the company misled investors about CVS Caremark's formulary and coverage approval timeline for its epinephrine nasal spray, neffy. The lawsuit covers investors who purchased SPRY shares between March 9, 2026 and June 24, 2026, with a lead plaintiff filing deadline of October 5, 2026.</p><h5>Complaint alleges ARS knew of CVS Caremark approval delays before disclosure</h5><p>The complaint charges that ARS Pharmaceuticals was aware its timeline for securing CVS Caremark formulary and coverage decisions on neffy faced obstacles that would directly impact the company's commercialization plans. Despite this internal knowledge, ARS allegedly continued issuing public statements that were false and materially misleading throughout the class period, in violation of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and SEC Rule 10b-5.</p><h5>Shareholders who bought SPRY shares in the 15-week window face an October 5 deadline</h5><p>Investors who acquired ARS Pharmaceuticals stock during the roughly 15-week class period are being urged to contact DJS Law Group regarding potential lead plaintiff appointments. Appointment as lead plaintiff is not a prerequisite for shareholders to participate in any eventual recovery.</p><h5>DJS Law Group specializes in securities and corporate governance litigation</h5><p>David J. Schwartz, founding partner of Schall Brown & Schwartz LLP and head of DJS Law Group, is pursuing the case. The firm's client base includes hedge funds and alternative asset managers pursuing securities class actions, corporate governance litigation, and M&A appraisal claims.</p>", "meta_description": "DJS Law Group files securities class action against ARS Pharmaceuticals over alleged misleading statements on neffy's CVS Caremark approval delays.", "seo_keywords": "ARS Pharmaceuticals, SPRY, securities class action, neffy, CVS Caremark, DJS Law Group, investor lawsuit", "companies": ["ARS Pharmaceuticals, Inc.", "DJS Law Group", "CVS Caremark"], "industries": ["Biopharmaceuticals"], "markets_regions": ["United States"], "news_type": ["legal_action", "financial_disclosure"], "products": ["neffy"], "themes": ["regulatory_compliance", "investor_relations"], "events": [], "cta_text": "Shareholders who purchased SPRY shares during the class period can contact DJS Law Group regarding lead plaintiff appointments.", "learn_more": "", "fact_check": {"accuracy_score": 100, "legal_risk": "low", "corrections_made": [], "recommendation": "publish"}}